FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of chemistry and pharmaceuticals. Object 1 constitutes a pharmaceutical composition containing (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethinyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl-1-pyrrolidinyl)-2-propene-1-one or a pharmaceutically acceptable salt thereof and sodium lauryl sulphate. Objects 2 to 4 constitute methods for improving the dissolution and absorption of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethinyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl-1-pyrrolidinyl)-2-propene-1-one and improving the producability of the pharmaceutical composition, including addition of sodium lauryl sulphate to the pharmaceutical composition containing (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethinyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl-1-pyrrolidinyl)-2-propene-1-one or a pharmaceutically acceptable salt thereof. Objects 5 to 8 constitute an application of sodium lauryl sulphate for improving the dissolution and absorption of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethinyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl-1-pyrrolidinyl)-2-propene-1-one or a pharmaceutically acceptable salt thereof for production and improvement of the producability of the pharmaceutical composition.
EFFECT: improved dissolution, stability, absorption and production of the pharmaceutical composition containing (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethinyl-1H-pyrazolo[3,4-d]pyrimidine-1-yl-1-pyrrolidinyl)-2-propene-1-one or a pharmaceutically acceptable salt thereof due to theaddition og sodium lauryl sulphate.
14 cl, 1 dwg, 10 tbl, 10 ex
